Table 3. Risk of asynchronous contralateral primary breast cancer associated with chemotherapy regimen stratified by BRCA1/2 mutation carrier status.
| Non-carriers | Carriers | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Bilateral | Unilateral | Bilateral | Unilateral | |||||
| n (%) | n (%)1 | RR2 | 95% CI | n (%) | n (%)1 | RR2 | 95% CI | p-value3 | |
| No Chemotherapy | 343 (57.4) | 611 (43.6) | 1.0 | (ref) | 41 (38.0) | 17 (23.2) | 1.0 | (ref) | |
| Chemotherapy Type4,5 | |||||||||
| CMF | 123 (20.6) | 421 (29.5) | 0.6 | 0.4-0.7 | 30 (27.8) | 26 (36.7) | 0.4 | 0.2-0.9 | 0.24 |
| CEF/CAF | 48 (8.0) | 95 (8.9) | 0.8 | 0.5-1.2 | 9 (8.3) | 14 (17.7) | 0.3 | 0.1-0.8 | 0.10 |
| Other anthracycline- based regimen |
45 (7.5) | 102 (8.7) | 0.7 | 0.5-1.2 | 18 (16.7) | 10 (14.3) | 0.9 | 0.3-2.6 | 0.27 |
| Multiple/other regimens | 14 (2.3) | 46 (4.2) | 0.4 | 0.2-0.8 | 7 (6.5) | 5 (7.2) | 0.7 | 0.2-3.3 | 0.19 |
1
Weighted percentages
2
Rate Ratios (RR) and 95% CIs are adjusted for age at first diagnosis.
3
Testing heterogeneity between carriers and non-carriers
4
A: adriamycin; C: cyclophosphamide; E: epirubicin; F: 5-fluorouracil; M: methotrexate
5
Numbers may not sum to total because of missing information